Isocitrate dehydrogenase 1 mutations in melanoma frequently co-occur with NRAS mutations

Histopathology
Konstantinos Linos, Laura J Tafe

Abstract

Isocitrate dehydrogenase 1 (IDH1) is a metabolic enzyme that converts isocitrate to α-ketoglutarate. IDH1 mutations are associated with the accumulation of the oncometabolite D-2-hydroxyglutarate, which acts as an epigenetic modifier, and the development of multiple malignancies. From May 2013 to June 2017, 252 melanoma samples from 214 patients with advanced or distant metastatic disease were tested for somatic mutations with the 50-gene AmpliSeq version 2 Cancer Hotspot Panel. Two hundred and twenty-six samples were sequenced successfully from 206 patients with 26 samples being characterised as quantity not sufficient. Melanomas from 10 separate patients (4.9%) were positive for IDH1 R132C (nine) or R132S (one). In six cases, the tumours also had a co-existing NRAS mutation (p.Q61R, Q61L and Q61K in two patients each) (P = 0.0044), whereas three patients had BRAF non-V600E mutations (V600K, V600G and V600R). Two cases had a TP53 variant, two cases an ATM variant, one a CDKN2A variant and one had an APC variant. The patients' ages ranged from 45 to 82 years (mean = 65.3, median = 65 years) and three of 10 patients were female (M:F ratio = 2:3). Three patients were stage 3 and seven were stage 4. Two are deceased, five are aliv...Continue Reading

References

Jan 27, 2000·Cell·D Hanahan, R A Weinberg
Sep 6, 2008·Science·D Williams ParsonsKenneth W Kinzler
Feb 21, 2009·The New England Journal of Medicine·Hai YanDarell D Bigner
May 23, 2009·Science·Matthew G Vander HeidenCraig B Thompson
Aug 7, 2009·The New England Journal of Medicine·Elaine R MardisTimothy J Ley
Nov 26, 2009·Nature·Lenny DangShinsan M Su
Mar 26, 2010·The New England Journal of Medicine·Jan Smeitink
Jul 7, 2010·Biochemical and Biophysical Research Communications·Giselle Y LopezHai Yan
Aug 10, 2010·Trends in Molecular Medicine·Lenny DangShinsan M Su
Sep 18, 2010·Science·Martijn KranendijkGajja S Salomons
Dec 22, 2010·American Journal of Clinical Pathology·Keyur P PatelRajyalakshmi Luthra
Jan 20, 2011·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Laura HeldJürgen Bauer
Mar 2, 2011·The American Journal of Pathology·Tatsuhiro ShibataNaoya Yamazaki
Jul 19, 2011·Trends in Molecular Medicine·Nuno RaimundoGerald S Shadel
Oct 17, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hui YangYue Xiong
May 1, 2013·Genes & Development·Julie-Aurore Losman, William G Kaelin
Dec 18, 2013·Clinical Chemistry and Laboratory Medicine : CCLM·Gregory J TsongalisChristopher I Amos
Jan 31, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Darrell R BorgerAndrew X Zhu
Oct 31, 2014·The American Journal of Dermatopathology·Banu YamanGülşen Kandiloğlu
Nov 30, 2014·Virchows Archiv : an International Journal of Pathology·M Fernanda AmaryAdrienne M Flanagan
May 29, 2015·American Journal of Hematology·Courtney D DiNardoHagop Kantarjian
Jun 11, 2015·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkJianan Zhang
Jun 20, 2015·Cell·UNKNOWN Cancer Genome Atlas Network
Nov 11, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Eytan M Stein
Mar 24, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L DangE C Attar
Dec 4, 2016·Cancer Research·Sarah ChiangStuart J Schnitt
Aug 22, 2017·Experimental and Molecular Pathology·Allen P MiraflorShaofeng Yan

❮ Previous
Next ❯

Citations

Nov 15, 2018·Expert Review of Molecular Diagnostics·Alberto PiccaMarc Sanson
Dec 19, 2019·Antioxidants & Redox Signaling·Petr Ježek
Aug 1, 2020·The American Journal of Surgical Pathology·Nicolas MacagnoArnaud de la Fouchardière
Aug 14, 2019·Pigment Cell & Melanoma Research·Elisa BertoliAlessandro Marco Minisini
Apr 20, 2021·Cancer Metastasis Reviews·Hendrik Hld VandyckVéronique Winnepenninckx
Jul 3, 2021·Cancers·Antonella MancaDaniela Massi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cellular Immunometabolism

Immunometabolism involves not only the way metabolites are digested by the immune system, but the way in which they can alter the pathway of the immune system. These responses occur in day-to-day healthy cell functioning, but can result in diseases, such as autoimmune disorders. Discover the latest research on cellular immunometabolism here.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.